Consolidation in multiple myeloma – current status and perspectives

Magdalena Olszewska-Szopa; Piotr Rzepecki

doi:10.5114/wo.2014.45983

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2014
vol. 18

Send email

Copy url:

abstract:

Review paper

Consolidation in multiple myeloma – current status and perspectives

Magdalena Olszewska-Szopa

,

Piotr Rzepecki

Contemp Oncol (Pozn) 2014; 18 (5): 313–317

DOI: https://doi.org/10.5114/wo.2014.45983

Online publish date: 2014/11/05

View full text Get citation

PlumX metrics:

Although multiple myeloma (MM) is still considered an incurable disease, the treatment philosophy is changing due to the introduction of novel agents. Standard treatment consists of an induction phase and autologous stem cell transplantation in patients under 65–70 years. Prolonged treatment (consolidation and/or maintenance) is being introduced in many countries. We present a review of clinical trials dedicated to consolidation treatment in multiple myeloma. Bortezomib, lenalidomide and carfilzomib in different combinations were tested in the trials mentioned below. Although they did not prolong overall survival, the data are very promising. Three very important large clinical trials are still in progress. The results might help to establish the actual value of consolidation treatment.

keywords:

Consolidation in multiple myeloma – current status and perspectives

Magdalena Olszewska-Szopa , Piotr Rzepecki

myeloma, consolidation, bortezomib, lenalidomide, ASCT

Magdalena Olszewska-Szopa

,

Piotr Rzepecki